Summary
- Krystal Biotech's VYJUVEK, a breakthrough gene therapy for DEB, generated revenues of $83.8m in 3Q 2024, doubling from 4Q 2023.
- At 57x 2024 earnings, Krystal's stock appears expensive but is expected to double in earnings by 2025.
- With the upcoming expansion of the EU and Japan market, Krystal seems poised to exceed analysts' growth expectations.
- VYJUVEK is a potential blockbuster as Krystal targets $1 billion in sales with its first commercialized drug.
- Krystal is capitalizing on its niche in redosable gene therapy with a compelling pipeline focused on multiple genetic diseases.
